(Q33400617)

English

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

Jean-Pierre Marolleau

16

object named as

Jean-Pierre Marolleau

0 references

object named as

Sylvie Chevret

21

0 references

Claude Preudhomme

object named as

Claude Preudhomme

20

0 references

19

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

26 July 2017

22

object named as

Hervé Dombret

1 reference

Europe PubMed Central

26 July 2017

2

object named as

Cécile Pautas

1 reference

Europe PubMed Central

26 July 2017

Emmanuel Raffoux

4

object named as

Emmanuel Raffoux

1 reference

Europe PubMed Central

26 July 2017

Dominique Bordessoule

5

object named as

Dominique Bordessoule

1 reference

Europe PubMed Central

26 July 2017

10

object named as

Oumedaly Reman

1 reference

Europe PubMed Central

26 July 2017

Sylvie Castaigne

1

object named as

Sylvie Castaigne

1 reference

Europe PubMed Central

26 July 2017

Philippe Rousselot

18

object named as

Philippe Rousselot

1 reference

Europe PubMed Central

26 July 2017

Christine Terré

3

object named as

Christine Terré

1 reference

Europe PubMed Central

26 July 2017

9

object named as

Pascal Turlure

1 reference

Europe PubMed Central

26 July 2017

Thierry de Revel

11

object named as

Thierry de Revel

1 reference

Europe PubMed Central

26 July 2017

Nathalie Contentin

14

object named as

Nathalie Contentin

1 reference

Europe PubMed Central

26 July 2017

Acute Leukemia French Association

23

object named as

Acute Leukemia French Association

1 reference

Europe PubMed Central

26 July 2017

author name string

Jean-Noel Bastie

6

1 reference

Europe PubMed Central

26 July 2017

Ollivier Legrand

7

1 reference

Europe PubMed Central

26 July 2017

Xavier Thomas

8

1 reference

Europe PubMed Central

26 July 2017

Lauris Gastaud

12

1 reference

Europe PubMed Central

26 July 2017

Noémie de Gunzburg

13

1 reference

Europe PubMed Central

26 July 2017

Estelle Henry

15

1 reference

Europe PubMed Central

26 July 2017

Jean-Pierre Marolleau

16

1 reference

Europe PubMed Central

26 July 2017

Ahmad Aljijakli

17

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

5 April 2012

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

379

1 reference

Europe PubMed Central

26 July 2017

9825

1 reference

Europe PubMed Central

26 July 2017

1508-1516

1 reference

Europe PubMed Central

26 July 2017

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal induction and post-remission therapy for AML in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing for qualitative interactions between treatment effects and patient subsets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose daunorubicin in older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960485-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(12)60485-1

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33400617&oldid=1962026754"